Australian (ASX) Stock Market Forum

NYR - Nyrada Inc.

Jump to new
System

System

Joined
27 June 2010
Posts
4,147
Reactions
309
Nyrada is a pre-clinical stage, drug development company specialising in the development of novel small molecule drugs pertaining to the underlying pathological processes involved in cardiovascular, neurodegenerative and chronic inflammatory diseases.

The Company's vision is to become a high growth bio-pharmaceutical company specialising in drug discovery and early stage drug development, based mainly around the benzopyran molecular scaffold and focusing on areas of substantial unmet clinical need, where few if any, effective or well-tolerated therapies exist.

The Company has four current drug development programs:
  • Cardiovascular: a PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs
  • Neuroprotection: a neuroprotectant drug to reduce the impact of long-term disability in patients with ischaemic stroke and traumatic brain injury
  • Inflammation/pain: a drug to treat pain associated with peripheral nerve damage, and
  • Inflammation/autoimmunity: a drug to treat autoimmune diseases such as psoriasis.
It is anticipated that NYR will list on the ASX during December 2019.

https://www.nyrada.com
 
From NOX announcement 18 Dec (slightly different):
The Boards of both Noxopharm Ltd (ASX:NOX) and Nyrada Inc are pleased to announce that commitments for the Maximum Subscription of $8,500,000 for the Nyrada Initial Public Offer (IPO) have been received.

The Company has been advised by the Lead Manager, Alto Capital, that the IPO Offer has been fully allocated and final reconciliation of funds are underway with formal closure of the Offer expected before Christmas. Nyrada can confirm that the Minimum Subscription of $7,000,000 has been received and is being held in trust.

Nyrada currently is in discussions with the ASX regarding confirmation of conditional approval requirements, however notes that further to recent ASX correspondence, conditional approval and an ASX listing of Nyrada is now expected in January 2020.

Nyrada is a U.S.-incorporated company established by Noxopharm in 2017 for the purpose of developing drugs across the three areas of cardiovascular, neurological and inflammatory diseases and disorders.
 
entered here at $0.305
next stop $0.37 then within months $0.55-0.60 as some potential profit taking range

Highlights:
  • Brain Injury Program Progress:
    • - New collaboration with the Walter Reed Army Institute of Research & UNSW Sydney
    • - Analogue optimisation underway to improve potency and drug-like qualities of
      neuroprotection compound, results expected in May
  • Cholesterol Program advancing:
    • - Exploratory data confirmed LDL (bad) cholesterol levels were lowered in a dose- dependent manner by NYX-PCSK9i
    • - New cholesterol study starting in April
  • Successful two-tranche capital raising of A$11 million: the first tranche raised A$7.2M with
    a second tranche to raise an additional $3.8M, subject to shareholder approval
  • Robust cash position of A$10.2 million: (including tranche 1) providing funding to progress both lead programs through to Phase I clinical trials
 
TechnoCap said:
entered here at $0.305
next stop $0.37 then within months $0.55-0.60 as some potential profit taking range

Highlights:
  • Brain Injury Program Progress:
    • - New collaboration with the Walter Reed Army Institute of Research & UNSW Sydney
    • - Analogue optimisation underway to improve potency and drug-like qualities of
      neuroprotection compound, results expected in May
  • Cholesterol Program advancing:
    • - Exploratory data confirmed LDL (bad) cholesterol levels were lowered in a dose- dependent manner by NYX-PCSK9i
    • - New cholesterol study starting in April
  • Successful two-tranche capital raising of A$11 million: the first tranche raised A$7.2M with
    a second tranche to raise an additional $3.8M, subject to shareholder approval
  • Robust cash position of A$10.2 million: (including tranche 1) providing funding to progress both lead programs through to Phase I clinical trials
Click to expand...
first milestone target hit yesterday at 37c (actually hit 37.5c) now a slight pullback today on low volume - buckle in for mid 50s next
 
16% rise so far today but on pretty weak volume.
One of Tony Locantro's rave biotech picks for 2022. Share price has performed abysmally to date.
The foreshadowed European patent might tempt a pharma to board?
Not Held.

Screenshot_20220517-145819_Drive.jpg



big - 2022-05-17T150016.301.gifScreenshot_20220517-150057_Drive.jpg
 
and YOWSERS !! on news
.
Screenshot_20240228-142522_CommSec~2.jpg

.
Statistically Significant Neuroprotection Achieved in Nyrada’s Preclinical Brain Injury Study

Highlights:
• Nyrada’s lead Brain Injury Program drug candidate NYR-BI03 demonstrated strong efficacy in reducing injury in a preclinical study.
• NYR-BI03 is a first-in-class therapy with a novel mechanism of action targeting significant market opportunity.
• Supporting NYR-BI03's favourable safety profile, the current study had no drug-related adverse effects.
• Good Laboratory Practice (GLP) safety testing to commence this current quarter.
• Walter Reed Army Institute of Research (US Military) brain injury study to commence this current quarter.
• Phase I clinical trial scheduled for the second half of the 2024 calendar year.
 
finicky said:
Early days.
Tony Locantro will be grilling himself a rump steak though.

Not Held
Click to expand...
I agree. Looks to be a bit overdone. I suspect it will end in tears when the music stops.

It’s a pre-clinical study based on 16 test animals and the actual Phase I trial isn't scheduled until the second half of 2024 as you say.
 
It has only occurred to me now that you meant 'stark' as in 'grim or ominous' because it's red, rather than a particular TA candle called 'Stark Candle'. :roflmao:
 
Nyrada Limited (ASX:NYR) CEO James Bonnar discusses results for using NYR-BI03 to treat brain injuries.

Paul Sanger: I’m Paul Sanger for the Finance News Network, and today I’m talking to Nyrada Inc (ASX:NYR), and they have a market cap of $14m. Nyrada is a drug discovery and development company specialising in novel small-molecule therapeutics to treat neurological and cardiovascular diseases. Their brain injury program is seeking to develop therapies to reduce the long-term disability associated with stroke or traumatic brain injury by limiting the progressive cell death that occurs as a secondary brain injury. Today, we’re talking to the company’s Chief Executive Officer, James Bonnar. James, welcome back to the network.

James Bonnar: Hi, Paul. Good to be here.

Paul Sanger: Now, James, you’ve released some significant news to the market today, positive results for your preclinical study evaluating the efficacy of your brain injury program drug candidate NYR-BI03. Can you please walk us through the study results?

James Bonnar: Certainly, Paul. So, the results we announced today were the result of a study in stroke. This was a study in a mouse model, and very pleasingly we were able to show in this study a better than 40 per cent neuroprotection, which certainly far exceeded our expectations. Also in this study, we were able to achieve a really strong signal in a blood injury biomarker. So, that supports the key finding. In addition to that, we also looked at safety in this study. So, we were pleased to report that there were no adverse effects in these animals that received our drug, so very, very pleasing results and happy to report them to the market.

Paul Sanger: So just moving on, so what do these results actually mean for Nyrada and what would be the next steps for the brain injury program following these results?

James Bonnar: So, this is a key inflection point for the program, and it sets up the way forward into some studies that we have to run. These are mandatory safety studies before we go into a first-in-human clinical study. So, this drug is novel, it’s never been tested before. And before we go into a first-in-human study, which we’re planning to run later in the year here in Australia, we have to test the drug in animals just to make sure that they tolerate it well and also identify the dose that we’re going to take into the clinical study.

Paul Sanger: And look, a typical question I ask with biotechs, what discussions, if any, have you had with potential partners or is it too early to develop those conversations?

James Bonnar: Well, it’s fairly early in this program. I think there’s a lot of interest in neurology drugs, particularly drugs that have first-in-class potential, which this drug does, and in therapeutic areas where there’s unmet need, but also large commercial opportunities. So, we’re developing this drug as a treatment for stroke, but also for traumatic brain injury. So, if you think of motor vehicle accidents, severe blows to the head, falls, etc. And the program that we’re running really opens the door to two quite large and significant indications. These represent severe unmet clinical need. For example, here in Australia, stroke occurs about every 20 minutes. So, annually there are about 13 million strokes worldwide, and the numbers are similar for traumatic brain injury. So, we see this as a major step forward for the company and opening up quite a sizable commercial opportunity.

Paul Sanger: And just to close things up, James, what should investors be expecting over the next six months? Any data points they should be looking for? What can they expect?

James Bonnar: So, we’re just about to initiate those safety studies, so we’ll be reporting readouts from those studies. We’re also running a study with the Walter Reed Army Institute of Research, and this is a division of the US Department of Defense, and they were set up specifically to research traumatic brain injury, and they’ve been big supporters of the program and they have a model that we want to test the drug in, and it’s a model of penetrating ballistic brain injury. So, it kind of reflects the sort of injuries that soldiers receive on the battlefield. So, that study’s about to get underway and we’ll be reporting on that and we’ll be giving regular updates to the market as we progress forward to the clinic.

Paul Sanger: James, a huge congratulations to yourself and to the broader team at Nyrada. Great to see these really impressive results, and we’ll be watching the story very closely going forward.

James Bonnar: Thanks, Paul.
.
Screenshot_20240302-101020_CommSec.jpg
 
verce said:
I agree. Looks to be a bit overdone. I suspect it will end in tears when the music stops.

It’s a pre-clinical study based on 16 test animals and the actual Phase I trial isn't scheduled until the second half of 2024 as you say.
Click to expand...
Capital raising.
 
And down to 10c

Highlights:
• Lead Brain Injury Program drug candidate NYR-BI03 demonstrated strong efficacy:
- rescued average 42% of the brain injury in the penumbra region.
• Good Laboratory Practice (GLP) safety testing studies have commenced and are expected to conclude in 1HFY2025.
• First in-human Phase I clinical trial of NYR-BI03 on track to start in 2QFY2025.
• Cash position of A$5.60 million as at 31 March 2024.
• Fully subscribed placement successfully raised A$1.76 million (before costs).
 
Up 70%
One of Tony Locantro's Krazy Klark's biotech specials from back in 2022.
Said he was going to paper the walls with buy contracts for these or something. Still only 11c.
Not Held
Don't care

Screenshot_20241001_153207_OneDrive.jpg

Screenshot_20241001_152453_Chrome.jpg
 
Top